You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Overview of clinical trials investigating targets within the adenosine signaling pathway in cancer

From: Targeting adenosine for cancer immunotherapy

Molecular Target ClinicalTrials.gov Identifier Pharmaceutical Supplier Agent Design Overview
Interventional Trials
A2aR NCT02655822 Corvus CPI-444 Phase 1/1b single agent and in combination with Atezolizumab allows prior PD-1/PD-L1 advanced solid malignancies
NCT02403193 Pablobio (Novartis) PBF-509 Phase 1/1b single agent and in combination PDR001 (anti-PD1) allows prior PD-1/PD-L1 non-small cell lung cancer
NCT03099161 Merck MK-3814 Phase 1 single agent and in combination with Pembrolizumab(anti-PD-1); allows prior PD-1/PD-L1 advanced solid malignancies
NCT02740985 AstraZeneca AZD4635 Phase 1 single agent and in combination with Durvalumab (anti-PDL-1) allows prior PD-1/PD-L1 advanced solid malignancies
CD73 NCT02503774 Medimmune MEDI9447 Phase 1 combination with Durvalumab (anti-PDL-1) (no single agent) allows prior PD-1/PD-L1 advanced solid malignancies
NCT03267589 Medimmune MEDI9447 Phase 2 single agent and in combination with Durvalumab (anti-PDL-1), Tremelilumab (anti-CTLA4), MEDI 0562 (anti-OX40) allows prior PD-1/PD-L1 relapsed ovarian cancer
NCT02754141 Bristol-Meyers-Squibb BMS-986179 Phase 1/2a single agent and in combination with Nivolumab (anti-PD-1) allows prior PD-1/PD-L1 advanced solid malignancies
Noninterventional Trialsa
CD39/CD73 NCT03255252 Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy
NCT02567929 Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patients With Breast Cancer
  1. a‚ÄúNoninterventional trials‚ÄĚ refers to interventions targeting the adenosine-CD39-CD73-A2aR pathway, these trials may be otherwise interventional in terms of other treatment modalities, such as chemotherapy or radiation